Preserving Skeletal Muscle and Function During GLP-1 Receptor Agonist Therapy: An Evidence-Informed Exercise Prescription Framework
DOI:
https://doi.org/10.12775/QS.2026.68.74482Keywords
GLP-1, GLP-1RA, semaglutide, tirzepatide, sarcopenia, resistance training, muscle quality, anabolic resistance, lean body mass, physical activity, lifestyle, lifestyle modificationAbstract
Background & Aim: GLP-1 RAs (e.g., semaglutide) and dual GIP/GLP-1 RAs (tirzepatide) induce substantial weight loss, but ~25% derives from fat-free mass (FFM). Whether this threatens skeletal muscle remains contested. Standard guidelines offer generic resistance training advice, ignoring the drugs' gastrointestinal and behavioral side effects. This narrative review aims to synthesize mechanisms of GLP-1 RA-associated lean mass loss, critique DXA-derived FFM as a clinical endpoint, shift focus to muscle quality/function, and propose a tailored exercise and nutritional framework.
Material and Methods: Literature, guidelines, meta-analyses, and clinical trials regarding GLP-1 RA body composition, muscle physiology, training methodology, and sports nutrition were synthesized. Recommendations were graded using a 4-tier hierarchy: direct clinical evidence, indirect evidence, mechanistic rationale, and expert inference.
Results: FFM loss (~25%) is heterogeneous and method-dependent. A model of drug-associated anabolic resistance (negative energy balance, protein intake below the per-meal leucine threshold, and reduced NEAT) explains this loss without direct muscle toxicity. DXA-FFM is a biased proxy for muscle; MRI and functional data suggest muscle quality may improve despite mass declines. Four distinct clinical barriers were identified: unreliable self-assessment of gastric motility, chronic nausea/fatigue, severe appetite suppression, and a gap in structured guidance. A framework of 20 tailored recommendations was developed (3 based on direct evidence, 17 on indirect/mechanistic data).
Conclusions: GLP-1 RA-associated muscle loss is a real, unevenly distributed risk mitigable via barrier-adapted resistance training and nutritional optimization. The proposed framework is physiologically plausible but requires prospective validation. Intervention is highly indicated for patients with low baseline muscle reserve, advanced age, prior bariatric surgery, CKD, or HFrEF.
References
Abraham, R., Foong, D., Piya, M., Grudzinskas, K., & Ho, V. (2026). Semaglutide induces changes in gastric electrical activity in patients with overweight and obesity: A pilot study. Journal of Neurogastroenterology and Motility, 32(2), 237–243. https://doi.org/10.5056/jnm25156
Alissou, M., Demangeat, T., Folope, V., et al. (2026). Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes, Obesity and Metabolism, 28(1), 112–121. https://doi.org/10.1111/dom.70141
Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. P.; SURMOUNT-5 Trial Investigators. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine, 393(1), 26–36. https://doi.org/10.1056/NEJMoa2416394
Babazadeh, D., Wyatt, S., & Steinberg, F. M. (2025). Examining the omission of dietary quality data in glucagon-like peptide 1 clinical trials: A scoping review. Advances in Nutrition, 16(10), 100491. https://doi.org/10.1016/j.advnut.2025.100491
Beddoe, A. H., Streat, S. J., & Hill, G. L. (1985). Hydration of fat-free body in protein-depleted patients. American Journal of Physiology, 249(2 Pt 1), E227–E233. https://doi.org/10.1152/ajpendo.1985.249.2.E227
Bhandarkar, A., Bhat, S., & Kapoor, N. (2025). Effect of GLP-1 receptor agonists on body composition. Current Opinion in Endocrinology, Diabetes and Obesity, 32(6), 279–285. https://doi.org/10.1097/MED.0000000000000934
Borner, T., Pataro, A. M., Doebley, S. A., et al. (2025). Hypophagia and body weight loss by tirzepatide are accompanied by fewer gastrointestinal adverse events compared to semaglutide in preclinical models. Science Advances, 11(25), eadu1589. https://doi.org/10.1126/sciadv.adu1589
Cannavaro, D., Leva, F., Caturano, A., Berra, C. C., Bonfrate, L., & Conte, C. (2025). Optimizing body composition during weight loss: The role of amino acid supplementation. Nutrients, 17(12), 2000. https://doi.org/10.3390/nu17122000
Cowley, N., Nicholson, V., Timmins, R., et al. (2025). The effects of percentage-based, rating of perceived exertion, repetitions in reserve, and velocity-based training on performance and fatigue responses. Journal of Strength and Conditioning Research, 39(4), e516–e529. https://doi.org/10.1519/JSC.0000000000005026
Delpino, F. M., Figueiredo, L. M., Forbes, S. C., Candow, D. G., & Santos, H. O. (2022). Influence of age, sex, and type of exercise on the efficacy of creatine supplementation on lean body mass: A systematic review and meta-analysis of randomized clinical trials. Nutrition, 103–104, 111791. https://doi.org/10.1016/j.nut.2022.111791
Deurenberg, P. (1996). Limitations of the bioelectrical impedance method for the assessment of body fat in severe obesity. American Journal of Clinical Nutrition, 64(3 Suppl), 449S–452S. https://doi.org/10.1093/ajcn/64.3.449S
Donini, L. M., Busetto, L., Bischoff, S. C., et al. (2022). Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obesity Facts, 15(3), 321–335. https://doi.org/10.1159/000521241
Hermann, T., Mohan, A. E., Enes, A., et al. (2025). Without fail: Muscular adaptations in single-set resistance training performed to failure or with repetitions in reserve. Medicine & Science in Sports & Exercise, 57(9), 2021–2031. https://doi.org/10.1249/MSS.0000000000003728
Heymsfield, S. B., Aronne, L. J., Montgomery, P., Klickstein, L. B., Coleman, L. A., Dole, K., Mindeholm, L., Spruill, S., Li, X., & Attie, K. M.; BELIEVE Trial Investigators. (2026). Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: A randomized phase 2 trial. Nature Medicine, 32(3), 869–882. https://doi.org/10.1038/s41591-026-04204-0
Hocking, S. L., Scott, D. A., Remedios, M. L., Horowitz, M., et al. (2025). 2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations on the peri-procedural use of GLP-1/GIP receptor agonists. Anaesthesia and Intensive Care, 53(5), 300–306. https://doi.org/10.1177/0310057X251355288
Jansson, A. K., Gómez-Martín, M., Hedin, L., Clarke, E. D., Cross, V., Stanford, J., Taylor, R. M., Bogl, L. H., De Vlieger, N., Koochek, A., Löf, M., Asher, R. C., Burrows, T., Bucher, T., Sullivan, C., Nowicka, P., & Collins, C. E. (2026). A systematic review identifying critical evidence gaps in reporting dietary change in randomized controlled trials prescribing liraglutide, semaglutide, or tirzepatide. Obesity Reviews. Advance online publication. https://doi.org/10.1111/obr.70077
Johnson Stoklossa, C. A., Forhan, M., Padwal, R. S., Gonzalez, M. C., et al. (2016). Practical considerations for body composition assessment of adults with class II/III obesity using bioelectrical impedance analysis or dual-energy X-ray absorptiometry. Current Obesity Reports, 5(4), 389–396. https://doi.org/10.1007/s13679-016-0228-5
Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025). Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism, 164, 156113. https://doi.org/10.1016/j.metabol.2024.156113
Katsanos, C. S., Liu, Z., & Atherton, P. J. (2026). Glucagon-like peptide-1 receptor agonism and muscle health: Vascular and myocellular effects on glucose and protein metabolism. Comprehensive Physiology, 16(2), e70126. https://doi.org/10.1002/cph4.70126
Koch, K. L., Van Natta, M., Parkman, H. P., et al. (2023). Effect of liquid and solid test meals on symptoms and gastric myoelectrical activity in patients with gastroparesis and functional dyspepsia. Neurogastroenterology & Motility, 35(2), e14376. https://doi.org/10.1111/nmo.14376
Kouw, I. W. K., Parr, E. B., Wheeler, M. J., Radford, B. E., Hall, R. C., Senden, J. M., Goessens, J. P. B., van Loon, L. J. C., & Hawley, J. A. (2024). Short-term intermittent fasting and energy restriction do not impair rates of muscle protein synthesis: A randomised, controlled dietary intervention. Clinical Nutrition, 43(11), 2536–2546. https://doi.org/10.1016/j.clnu.2024.09.034
Krajnc, M., Kuhar, N., & Koceva, A. (2025). Oral semaglutide for the treatment of obesity: A retrospective real-world study. Frontiers in Endocrinology, 16, 1593334. https://doi.org/10.3389/fendo.2025.1593334
Locatelli, J. C., Costa, J. G., Haynes, A., Naylor, L. H., Fegan, P. G., Yeap, B. B., & Green, D. J. (2024). Incretin-based weight loss pharmacotherapy: Can resistance exercise optimize changes in body composition? Diabetes Care, 47(10), 1718–1730. https://doi.org/10.2337/dci23-0100
Look, M., Dunn, J. P., Kushner, R. F., et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 27(5), 2720–2729. https://doi.org/10.1111/dom.16275
Maharjan, S., Dangol, G., & Le, Q. (2026, June 13–16). Losing pounds, not gaining steps: The paradox of GLP-1 receptor agonist therapy [Conference abstract]. ENDO 2026, Annual Meeting of the Endocrine Society, Chicago, IL, United States.
Malavaki, C. J., Sakkas, G. K., Mitrou, G. I., et al. (2015). Skeletal muscle atrophy: Disease-induced mechanisms may mask disuse atrophy. Journal of Muscle Research and Cell Motility, 36(6), 405–421. https://doi.org/10.1007/s10974-015-9439-8
Mechanick, J. I., Butsch, W. S., Christensen, S. M., Hamdy, O., Li, Z., Prado, C. M., & Heymsfield, S. B. (2025). Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obesity Reviews, 26(1), e13841. https://doi.org/10.1111/obr.13841
Murphy, C., & Koehler, K. (2020). Caloric restriction induces anabolic resistance to resistance exercise. European Journal of Applied Physiology, 120(5), 1155–1164. https://doi.org/10.1007/s00421-020-04354-0
Murphy, C., & Koehler, K. (2022). Energy deficiency impairs resistance training gains in lean mass but not strength: A meta-analysis and meta-regression. Scandinavian Journal of Medicine & Science in Sports, 32(1), 125–137. https://doi.org/10.1111/sms.14075
Nalbandian, M., et al. (2026). 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist–induced weight loss. Proceedings of the National Academy of Sciences, 123(23), e2606533123. https://doi.org/10.1073/pnas.2606533123
Neeland, I. J., Linge, J., & Birkenfeld, A. L. (2024). Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism, 26(Suppl. 4), 16–27. https://doi.org/10.1111/dom.15728
Noronha, J. C., Van Gaal, L. F., Neeland, I. J., et al. (2025). Optimizing GLP-1 therapies for obesity and diabetes management. Obesity Pillars, 16, 100222. https://doi.org/10.1016/j.obpill.2025.100222
Nunn, E., Jaiswal, N., Gavin, M., et al. (2024). Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. Molecular Metabolism, 80, 101880. https://doi.org/10.1016/j.molmet.2024.101880
Orioli, L., Thissen, J. P., & Loumaye, A. (2026). Changes in body composition, muscle function, and muscle insulin sensitivity induced by obesity and bariatric surgery. Clinical Nutrition, 56, 106547. https://doi.org/10.1016/j.clnu.2025.106547
Pourhassan, M., Schautz, B., Braun, W., Gluer, C. C., Bosy-Westphal, A., & Müller, M. J. (2013). Impact of body-composition methodology on the composition of weight loss and weight gain. European Journal of Clinical Nutrition, 67(5), 446–454. https://doi.org/10.1038/ejcn.2013.35
Regeneron Pharmaceuticals. (2026). Interim results from ongoing phase 2 COURAGE trial confirm potential of trevogrumab-based combinations to preserve muscle during weight loss [Press release]. https://newsroom.regeneron.com/news-releases/news-release-details/interim-results-ongoing-phase-2-courage-trial-confirm-potential/
Ren, Q., Zhi, L., & Liu, H. (2025). Semaglutide therapy and accelerated sarcopenia in older adults with type 2 diabetes: A 24-month retrospective cohort study. Drug Design, Development and Therapy. Advance online publication. https://doi.org/10.2147/DDDT.S531778
Robinson, Z. P., Pelland, J. C., Remmert, J. F., Refalo, M. C., Jukic, I., Steele, J., & Zourdos, M. C. (2024). Exploring the dose-response relationship between estimated resistance training proximity to failure, strength gain, and muscle hypertrophy: A series of meta-regressions. Sports Medicine, 54(9), 2209–2231. https://doi.org/10.1007/s40279-024-02069-2
Saha, B., Kamalumpundi, V., & Codipilly, D. C. (2025). GLP-1 and GIP receptor agonists: Effects on the gastrointestinal tract and management strategies for primary care physicians. Mayo Clinic Proceedings. Advance online publication. https://doi.org/10.1016/j.mayocp.2025.09.017
Sattar, N., Neeland, I. J., Dahlqvist Leinhard, O., et al. (2025). Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI substudy). Lancet Diabetes & Endocrinology, 13(6), 482–493. https://doi.org/10.1016/S2213-8587(25)00027-0
Schoenfeld, B. J., Grgic, J., Van Every, D. W., & Plotkin, D. L. (2021). Loading recommendations for muscle strength, hypertrophy, and local endurance: A re-examination of the repetition continuum. Sports, 9(2), 32. https://doi.org/10.3390/sports9020032
Schumann, M., Feuerbacher, J. F., Sünkeler, M., Freitag, N., Rønnestad, B. R., Doma, K., & Lundberg, T. R. (2022). Compatibility of concurrent aerobic and strength training for skeletal muscle size and function. Sports Medicine, 52(3), 601–612. https://doi.org/10.1007/s40279-021-01587-7
Seliem, M. A., & Ragab, M. A. (2026). Molecular and cellular mechanisms of muscle–adipose tissue crosstalk driving sarcopenic obesity. Nutrition & Metabolism, 23, 57. https://doi.org/10.1186/s12986-026-01123-2
Skibicka, K. P. (2013). The central GLP-1: Implications for food and drug reward. Frontiers in Neuroscience, 7, 181. https://doi.org/10.3389/fnins.2013.00181
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024). The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health. Metabolism, 161, 156057. https://doi.org/10.1016/j.metabol.2024.156057
Tieland, M., van Dronkelaar, C., & Boirie, Y. (2019). Sarcopenic obesity in the ICU. Current Opinion in Clinical Nutrition and Metabolic Care, 22(2), 162–166. https://doi.org/10.1097/MCO.0000000000000547
Tinsley, G. M., & Heymsfield, S. B. (2024). Fundamental body composition principles provide context for fat-free and skeletal muscle loss with GLP-1 RA treatments. Journal of the Endocrine Society, 8(11), bvae164. https://doi.org/10.1210/jendso/bvae164
Vieira, F. T., Cai, Y., Gonzalez, M. C., Goodpaster, B. H., Prado, C. M., & Haqq, A. M. (2025). Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Reviews in Endocrine and Metabolic Disorders. Advance online publication. https://doi.org/10.1007/s11154-025-09941-0
Waters, D. L. (2019). Intermuscular adipose tissue: A brief review of etiology, association with physical function and weight loss in older adults. Annals of Geriatric Medicine and Research, 23(1), 3–8. https://doi.org/10.4235/agmr.19.0001
Zourdos, M. C., Klemp, A., Dolan, C., et al. (2016). Novel resistance training-specific rating of perceived exertion scale measuring repetitions in reserve. Journal of Strength and Conditioning Research, 30(1), 267–275. https://doi.org/10.1519/JSC.0000000000001049
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Michał Adamczak, Marcel Majewski, Bogumił Libura, Martyna Lazar, Łukasz Szkaradowski, Szymon Baranowski, Julia Lewańska, Krzysztof Bogdański, Zuzanna Kruszyńska, Anastasiya Aleshchyk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 228
Number of citations: 0
